San Diego-based Arcturus Therapeutics has received a grant of up to $10 million to develop a vaccine for the deadly strain of coronavirus known as COVID-19.
The company joins Inovio Pharmaceuticals, Moderna and others in working on vaccines, which if successful could take a year to reach the wider public, experts say.
The Singapore Economic Development Board, which awarded the grant, would get a cut of vaccine sales outside of Singapore, according to a regulatory filing.
Arcturus said its vaccine could be effective at lower doses than other RNA-based medicines, reducing the time and cost to vaccinate large populations. The company did not provide a timeline of when its program might begin clinical testing in humans.
COVID-19 cases stand at 97,800 globally, with 3,347 deaths, according to data compiled by Johns Hopkins University.
To fight the virus, Arcturus said its technology self-replicates RNA to produce critical proteins. The company received part of the grant upfront, with the full $10 million dependent on development milestones.
Arcturus is working with the Duke-NUS Medical School, a partnership between Duke University School of Medicine and the National University of Singapore.
The Business Journal is the premier business publication in San Diego. Every day online and each Monday in print, the Business Journal reports on how local business operate and why businesses leaders make the decisions they do. Every story is a dose of insight into how to run a better, more efficient, more profitable business.